A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization

被引:12
|
作者
Marsango, Sara [1 ]
Caltabiano, Gianluigi [2 ]
Jimemez-Roses, Mireia [2 ]
Millan, Mark J. [3 ]
Pediani, John D. [1 ]
Ward, Richard J. [1 ]
Milligan, Graeme [1 ]
机构
[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Ctr Translat Pharmacol, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Bellaterra 08193, Spain
[3] Ctr Innovat Neuropsychiat, Inst Rech Servier, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
基金
英国医学研究理事会;
关键词
PROTEIN-COUPLED RECEPTORS; M-1 MUSCARINIC RECEPTOR; D3; RECEPTOR; OLIGOMERIC ORGANIZATION; DIMERIZATION; INTERFACE; SEROTONIN; HETERODIMERIZATION; TRANSACTIVATION; SCHIZOPHRENIA;
D O I
10.1038/s41598-017-02249-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The dopamine D-3 receptor (D3R) is a molecular target for both first-generation and several recently-developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial Intensity Distribution Analysis indicated that a substantial proportion of the receptor was present within dimeric/oligomeric complexes and that increased expression levels of the receptor favored a greater dimer to monomer ratio. Addition of the antipsychotics, spiperone or haloperidol, resulted in re-organization of D3R quaternary structure to promote monomerization. This action was dependent on ligand concentration and reversed upon drug washout. By contrast, a number of other antagonists with high affinity at the D3R, did not alter the dimer/monomer ratio. Molecular dynamics simulations following docking of each of the ligands into a model of the D3R derived from the available atomic level structure, and comparisons to the receptor in the absence of ligand, were undertaken. They showed that, in contrast to the other antagonists, spiperone and haloperidol respectively increased the atomic distance between reference a carbon atoms of transmembrane domains IV and V and I and II, both of which provide key interfaces for D3R dimerization. These results offer a molecular explanation for the distinctive ability of spiperone and haloperidol to disrupt D3R dimerization.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Novel selective dopamine D3 receptor modulators for the treatment of cocaine addiction
    Chen, Peng-Jen
    Blass, Benjamin
    Gordon, John
    Luedtke, Robert
    Taylor, Michelle
    Korzekwa, Kenneth
    Ye, Min
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [42] High-affinity and selective dopamine D3 receptor full agonists
    Chen, Jianyong
    Levant, Beth
    Wang, Shaomeng
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (17) : 5612 - 5617
  • [43] Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists
    Micheli, Fabrizio
    Cremonesi, Susanna
    Semeraro, Teresa
    Tarsi, Luca
    Tomelleri, Silvia
    Cavanni, Paolo
    Oliosi, Beatrice
    Perdona, Elisabetta
    Sava, Anna
    Zonzini, Laura
    Feriani, Aldo
    Braggio, Simone
    Heidbreder, Christian
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (04) : 1329 - 1332
  • [44] Identification and optimization of a potent and highly selective D3 dopamine receptor agonist
    Amy E MORITZ
    R Benjamin FREE
    Warren WEINER
    Muzna BACHANI
    Trevor DOYLE
    Noel SOUTHALL
    Marc FERRER
    Jonathan A JAVITCH
    Joseph STEINER
    Ara ABRAMYAN
    Lei SHI
    Jeffrey AUBé
    Kevin FRANKOWSKI
    David R SIBLEY
    [J]. 中国药理学与毒理学杂志, 2017, 31 (10) : 950 - 951
  • [45] Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists
    Duan, Xinli
    Zhang, Xin
    Xu, Binglin
    Wang, Fang
    Lei, Ming
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (01) : 142 - 154
  • [46] Molecular basis of alcohol intake: role of D3 dopaminergic receptor
    Platania, C. B.
    Leggio, G. M.
    Camillieri, G.
    Castorina, A.
    Torrisi, S. A.
    Nona, C. N.
    D'Agata, V.
    Nobrega, J.
    Le Foll, B.
    Drago, F.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S8 - S9
  • [47] PET imaging of dopamine D3 receptors in humans with [11C]-(+)-PHNO: Validation using a selective D3 antagonist
    Searle, Graham
    Beaver, John
    Comley, Robert
    Bani, Massimo
    Tziortzi, Andri
    Slifstein, Mark
    Wilson, Alan
    Gunn, Roger
    Rabiner, Eugenii
    Laruelle, Marc
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [48] Studies of New Fused Benzazepine as Selective Dopamine D3 Receptor Antagonists Using 3D-QSAR, Molecular Docking and Molecular Dynamics
    Liu, Jing
    Li, Yan
    Zhang, Shuwei
    Xiao, Zhengtao
    Ai, Chunzhi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2011, 12 (02) : 1196 - 1221
  • [49] Effects of the selective dopamine D3 receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice
    Botz-Zapp, Christian A.
    Foster, Stephanie L.
    Pulley, Desta M.
    Hempel, Briana
    Bi, Guo-Hua
    Xi, Zheng-Xiong
    Newman, Amy Hauck
    Weinshenker, David
    Manvich, Daniel F.
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2021, 415
  • [50] Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A
    Di Ciano, P
    Underwood, RJ
    Hagan, JJ
    Everitt, BJ
    [J]. NEUROPSYCHOPHARMACOLOGY, 2003, 28 (02) : 329 - 338